Is RXST or ECOR more profitable?

RxSight has a net margin of -36.58% compared to electroCore's net margin of -44.08%. RxSight's return on equity of -17.01% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% electroCore -44.08% -1,956.38% -83.30%

Is ECOR or FOCL more profitable?

FocalTherics has a net margin of -41.47% compared to electroCore's net margin of -44.08%. FocalTherics' return on equity of -137.61% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -44.08% -1,956.38% -83.30% FocalTherics -41.47% -137.61% -40.62%

Which has better earnings and valuation, ECOR or PDEX?

Pro-Dex has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio electroCore $32.03M 1.76 -$13.97M -$1.77 N/A Pro-Dex $66.59M 2.62 $8.98M $3.62 15.08

Is ECOR or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to electroCore's net margin of -44.08%. Pro-Dex's return on equity of 22.78% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -44.08% -1,956.38% -83.30% Pro-Dex 16.08% 22.78% 14.30%

electroCore (ECOR) Competitors

$6.25 -0.08 (-1.26%)

As of 01:56 PM Eastern

Compare

ECOR vs. RXST, FOCL, LUCD, PDEX, and KRMD

Should you buy electroCore stock or one of its competitors? MarketBeat compares electroCore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with electroCore include RxSight (RXST), FocalTherics (FOCL), Lucid Diagnostics (LUCD), Pro-Dex (PDEX), and KORU Medical Systems (KRMD). These companies are all part of the "medical equipment" industry.

How does electroCore compare to RxSight?

RxSight (NASDAQ:RXST) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, electroCore has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

electroCore has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.62	-$38.94M	-$1.13	N/A
electroCore	$32.03M	1.76	-$13.97M	-$1.77	N/A

78.8% of RxSight shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 13.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

RxSight has a net margin of -36.58% compared to electroCore's net margin of -44.08%. RxSight's return on equity of -17.01% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
electroCore	-44.08%	-1,956.38%	-83.30%

In the previous week, RxSight had 2 more articles in the media than electroCore. MarketBeat recorded 2 mentions for RxSight and 0 mentions for electroCore. RxSight's average media sentiment score of 0.47 beat electroCore's score of 0.00 indicating that RxSight is being referred to more favorably in the media.

Company	Overall Sentiment
RxSight	Neutral
electroCore	Neutral

RxSight presently has a consensus price target of $8.89, suggesting a potential upside of 68.51%. electroCore has a consensus price target of $18.00, suggesting a potential upside of 188.00%. Given electroCore's stronger consensus rating and higher probable upside, analysts plainly believe electroCore is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

RxSight beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to FocalTherics?

electroCore (NASDAQ:ECOR) and FocalTherics (NASDAQ:FOCL) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

26.7% of electroCore shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 13.8% of electroCore shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

electroCore has higher earnings, but lower revenue than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	1.76	-$13.97M	-$1.77	N/A
FocalTherics	$70.53M	3.25	-$29.25M	-$0.81	N/A

electroCore has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

electroCore currently has a consensus target price of $18.00, indicating a potential upside of 188.00%. FocalTherics has a consensus target price of $9.00, indicating a potential upside of 47.30%. Given electroCore's higher possible upside, equities analysts clearly believe electroCore is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

FocalTherics has a net margin of -41.47% compared to electroCore's net margin of -44.08%. FocalTherics' return on equity of -137.61% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
FocalTherics	-41.47%	-137.61%	-40.62%

In the previous week, FocalTherics had 3 more articles in the media than electroCore. MarketBeat recorded 3 mentions for FocalTherics and 0 mentions for electroCore. FocalTherics' average media sentiment score of 0.86 beat electroCore's score of 0.00 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Overall Sentiment
electroCore	Neutral
FocalTherics	Positive

Summary

FocalTherics beats electroCore on 11 of the 16 factors compared between the two stocks.

How does electroCore compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

electroCore has higher revenue and earnings than Lucid Diagnostics. electroCore is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	40.57	-$58.01M	-$0.47	N/A
electroCore	$32.03M	1.76	-$13.97M	-$1.77	N/A

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 13.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

electroCore has a net margin of -44.08% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
electroCore	-44.08%	-1,956.38%	-83.30%

Lucid Diagnostics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, electroCore has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

In the previous week, Lucid Diagnostics had 1 more articles in the media than electroCore. MarketBeat recorded 1 mentions for Lucid Diagnostics and 0 mentions for electroCore. electroCore's average media sentiment score of 0.00 beat Lucid Diagnostics' score of -0.71 indicating that electroCore is being referred to more favorably in the news media.

Company	Overall Sentiment
Lucid Diagnostics	Negative
electroCore	Neutral

Lucid Diagnostics presently has a consensus price target of $4.19, suggesting a potential upside of 345.01%. electroCore has a consensus price target of $18.00, suggesting a potential upside of 188.00%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, research analysts plainly believe Lucid Diagnostics is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lucid Diagnostics beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to Pro-Dex?

electroCore (NASDAQ:ECOR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

26.7% of electroCore shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 13.8% of electroCore shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

electroCore presently has a consensus target price of $18.00, indicating a potential upside of 188.00%. Pro-Dex has a consensus target price of $70.00, indicating a potential upside of 28.19%. Given electroCore's higher probable upside, analysts clearly believe electroCore is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has a net margin of 16.08% compared to electroCore's net margin of -44.08%. Pro-Dex's return on equity of 22.78% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Pro-Dex	16.08%	22.78%	14.30%

In the previous week, Pro-Dex had 2 more articles in the media than electroCore. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for electroCore. Pro-Dex's average media sentiment score of 1.26 beat electroCore's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
electroCore	Neutral
Pro-Dex	Positive

Pro-Dex has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	1.76	-$13.97M	-$1.77	N/A
Pro-Dex	$66.59M	2.62	$8.98M	$3.62	15.08

electroCore has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Summary

Pro-Dex beats electroCore on 12 of the 15 factors compared between the two stocks.

How does electroCore compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

KORU Medical Systems has higher revenue and earnings than electroCore. KORU Medical Systems is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13M	4.21	-$2.64M	-$0.05	N/A
electroCore	$32.03M	1.76	-$13.97M	-$1.77	N/A

In the previous week, KORU Medical Systems had 1 more articles in the media than electroCore. MarketBeat recorded 1 mentions for KORU Medical Systems and 0 mentions for electroCore. KORU Medical Systems' average media sentiment score of 0.00 equaled electroCore'saverage media sentiment score.

Company	Overall Sentiment
KORU Medical Systems	Neutral
electroCore	Neutral

KORU Medical Systems has a net margin of -5.27% compared to electroCore's net margin of -44.08%. KORU Medical Systems' return on equity of -13.61% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
electroCore	-44.08%	-1,956.38%	-83.30%

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by company insiders. Comparatively, 13.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

KORU Medical Systems has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, electroCore has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

KORU Medical Systems presently has a consensus target price of $7.25, suggesting a potential upside of 92.31%. electroCore has a consensus target price of $18.00, suggesting a potential upside of 188.00%. Given electroCore's higher possible upside, analysts clearly believe electroCore is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

KORU Medical Systems beats electroCore on 12 of the 15 factors compared between the two stocks.

Get electroCore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ECOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ECOR vs. The Competition

Export

Metric	electroCore	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.38M	$3.05B	$6.83B	$12.29B
Dividend Yield	N/A	2.04%	2.67%	9.42%
P/E Ratio	-3.53	20.17	26.82	23.83
Price / Sales	1.76	792.39	578.86	114.38
Price / Cash	N/A	28.08	50.60	60.45
Price / Book	-29.76	4.20	10.19	6.09
Net Income	-$13.97M	$65.94M	$3.60B	$331.73M
7 Day Performance	8.13%	-2.51%	-1.85%	-1.68%
1 Month Performance	-25.15%	-2.89%	-0.72%	-2.94%
1 Year Performance	-14.73%	10.64%	19.02%	14.43%

electroCore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ECOR electroCore	2.6789 of 5 stars	$6.25 -1.3%	$18.00 +188.0%	-10.0%	$56.38M	$32.03M	N/A	50
RXST RxSight	2.9017 of 5 stars	$4.92 -2.8%	$8.89 +80.7%	-25.8%	$209.47M	$134.48M	N/A	220
FOCL FocalTherics	3.5586 of 5 stars	$5.41 -0.4%	$6.00 +10.9%	N/A	$203.53M	$70.53M	N/A	230	High Trading Volume
LUCD Lucid Diagnostics	3.7403 of 5 stars	$1.00 +0.9%	$4.19 +318.8%	-16.0%	$201.26M	$4.71M	N/A	70	News Coverage Analyst Downgrade Gap Down
PDEX Pro-Dex	3.8077 of 5 stars	$58.26 -5.3%	$70.00 +20.2%	+12.1%	$196.51M	$66.59M	16.09	140	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ECOR) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

electroCore (ECOR) Competitors

ECOR vs. RXST, FOCL, LUCD, PDEX, and KRMD

How does electroCore compare to RxSight?

Summary

How does electroCore compare to FocalTherics?

Summary

How does electroCore compare to Lucid Diagnostics?

Summary

How does electroCore compare to Pro-Dex?

Summary

How does electroCore compare to KORU Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ECOR vs. The Competition

electroCore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

electroCore (ECOR) Competitors

ECOR vs. RXST, FOCL, LUCD, PDEX, and KRMD

How does electroCore compare to RxSight?

Which has more volatility & risk, RXST or ECOR?

Which has better earnings & valuation, RXST or ECOR?

Do institutionals and insiders hold more shares of RXST or ECOR?

Is RXST or ECOR more profitable?

Does the media prefer RXST or ECOR?

Do analysts prefer RXST or ECOR?

Summary

How does electroCore compare to FocalTherics?

Do insiders and institutionals have more ownership in ECOR or FOCL?

Which has better valuation & earnings, ECOR or FOCL?

Which has more risk & volatility, ECOR or FOCL?

Do analysts recommend ECOR or FOCL?

Is ECOR or FOCL more profitable?

Does the media prefer ECOR or FOCL?

Summary

How does electroCore compare to Lucid Diagnostics?

Which has preferable valuation and earnings, LUCD or ECOR?

Do insiders & institutionals believe in LUCD or ECOR?

Is LUCD or ECOR more profitable?

Which has more risk & volatility, LUCD or ECOR?

Does the media favor LUCD or ECOR?

Do analysts prefer LUCD or ECOR?

Summary

How does electroCore compare to Pro-Dex?

Do insiders and institutionals believe in ECOR or PDEX?

Do analysts recommend ECOR or PDEX?

Is ECOR or PDEX more profitable?

Does the media refer more to ECOR or PDEX?

Which has better earnings and valuation, ECOR or PDEX?

Which has more volatility and risk, ECOR or PDEX?

Summary

How does electroCore compare to KORU Medical Systems?

Which has better valuation & earnings, KRMD or ECOR?

Does the media favor KRMD or ECOR?

Is KRMD or ECOR more profitable?

Do institutionals & insiders believe in KRMD or ECOR?

Which has more volatility and risk, KRMD or ECOR?

Do analysts rate KRMD or ECOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ECOR vs. The Competition

electroCore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools